<section class="Section" data-sectioncode="34089-3"><a name="ID_9cc34126-3008-4e57-88c5-7daee81e6fae"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug.Xofigo is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8.Each milliliter of solution contains 1,100 kBq radium-223 dichloride (30 microcurie), corresponding to 0.58 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Each vial contains 6 mL of solution (6,600 kBq (178 microcurie) radium-223 dichloride at the reference date). The inactive ingredients are 6.3 mg/mL sodium chloride USP (tonicity agent), 7.2 mg/mL sodium citrate USP (for pH adjustment), 0.2 mg/mL hydrochloric acid USP (for pH adjustment), and water for injection USP.The molecular weight of radium-223 dichloride, 223RaCl2, is 293.9 g/mol.Radium-223 has a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq (51.4 microcurie)/ng.The six-stage-decay of radium-223 to stable lead-207 occurs via short-lived daughters, and is accompanied predominantly by alpha emissions. There are also beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5 - 7.5 MeV). The fraction emitted as beta-particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV). </section>

Xofigo

radium chloride Ra-223

6 ML radium chloride Ra-223 30 MCI/ML Injection

6 ML radium chloride Ra-223 30 MCI/ML Injection [Xofigo]

radium

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Submit MSL Request 

Pharmacy List

How To Order Xofigo

Billing & Coding Guide

Reimbursement Information

Coverage Authorization Request

Coverage Authorization Appeals

Letter of Medical Necessity

Enroll in Patient Savings Program

Xofigo Access Services Enrollment Form

Xofigo Access Services Enrollment Form - VA/DoD Only

Patient Counseling

Other HCP Resources

About Xofigo

Receiving Xofigo

Side Effects

While on Xofigo

Xofigo Support Program

Treatment Center Locator

Instructions For Use: Prostate Cancer 

Doctor Discussion Guide

Xofigo Access Support for Patients Brochure

Xofigo Patient Symptom Sheet

Patient Brochure

Patient Brochure - Spanish

Patient Treatment Guide

Patient Resources